[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"n-acetyl-glutamate---synthetase\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:n-acetyl-glutamate---synthetase":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":28,"conditions":29,"keywords":41,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":5},"100652398","phase-1-phase-12-study-of-krro-121-in-healthy-volunteers-and-patients-with-ucd-100652398",false,"NCT07773246","Phase 1\u002F2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD","A Phase 1\u002F2, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KRRO-121 in Healthy Volunteers and Patients With Urea Cycle Disorders","ANCHOR","Inclusion Criteria:\n\n* Adult male or female participants, 18 to 65 years of age\n* Healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and screening laboratory assessments, in the opinion of the Investigator.\n* Female participant of childbearing potential or male participant that is willing to use an approved, reliable means of contraception\n* Willing and able to provide signed written informed consent and to comply with all study requirements\n\nExclusion Criteria:\n\n* Any medical history that is clinically significant in the opinion of the Principal Investigator and Sponsor Medical Monitor\n* Any laboratory value at screening or predose on Day -1 outside the local laboratory reference range that is clinically significant in the opinion of the Principal Investigator and Sponsor Medical Monitor\n* Evidence of active systemic infection at Screening or Day 1 requiring antimicrobial, antiviral, or antifungal therapy\n* Use of any investigational drug or device within 3 months or 5 half-lives (whichever is longer) prior to Day 1\n* Concurrent participation in any other interventional clinical study",true,"ALL","18 Years","65 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26,27],"PHASE1","PHASE2","Phase 1\u002F2 Study of KRRO-121 is a randomized, placebo-controlled study in Healthy Volunteers (Phase 1 SAD and MAD) and Study Participants with Urea Cycle Disorders (Phase 2). The primary objective of the study is to evaluate the safety of KRRO-121.",[30,31,32,33,34,35,36,37,38,39,40],"Urea Cycle Disorders, Inborn","Urea Cycle Disorders","Ornithine Transcarbamylase (OTC) Deficiency","Arginase 1 Deficiency","NAGS Deficiency","Carbamylphosphate Synthetase I","Ornithine Transporter Mitochondrial 1","Argininosuccinate Synthase","Argininosuccinate Lyase Deficiency","N-acetyl Glutamate - Synthetase","Citrin Deficiency",[42,43,44,45],"KRRO-121","stabilized variant of glutamine synthetase (GS)","ammonia clearance","RNA-editing","NOT_YET_RECRUITING","2026-08-18",{"date":49,"type":50},"2026-08-20","ACTUAL",{"date":52,"type":23},"2026-09",{"date":54,"type":23},"2027-09",{"name":56,"class":57},"Korro Bio, Inc.","INDUSTRY"]